THE RESULTS OF COMBINED TREATMENT OF PATIENTS WITH METASTATIC GASTRIC CANCER. CASE STUDY
##article.numberofdownloads## 22
##article.numberofviews## 46
PDF (Русский)

How to Cite

, , , , , & . (2013). THE RESULTS OF COMBINED TREATMENT OF PATIENTS WITH METASTATIC GASTRIC CANCER. CASE STUDY. Voprosy Onkologii, 59(1), 123–125. https://doi.org/10.37469/0507-3758-2013-59-1-123-125

Abstract

There is presented the clinical observation of combined treatment of a patient with metastatic gastric cancer. The patient underwent combined chemotherapy for metastatic initially inoperative gastric cancer with metastases to the liver, paragastric lymph nodes as well as canceromatosis of the peritoneum with complete resorption of distant metastases, which allowed performing radical surgery. As a result of the combined treatment the patient is currently under dynamic observation without signs of disease. Duration of the patient’s life at the moment is 44 months.
https://doi.org/10.37469/0507-3758-2013-59-1-123-125
##article.numberofdownloads## 22
##article.numberofviews## 46
PDF (Русский)

References

Статистика злокачественных новообразований в России и странах СНГ в 2008 г. // Под ред. М.И. Давыдова, Е.М. Аксель) М. — 2010.

Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer // Ann Oncol. 1997. — Vol. 8. — P. 168.

Gorbunova V.A., Besova N.S., Orel F. et al. The efficacy and toxicity of Taxoter (T) + Cisplatin (P) + 5-FU (F) (TPF) as the first-line chemotherapy in advanced gastric cancer. Treatment possibilities in the elderly (aged 65 years). Final results // Ann Oncol. 2004. — Vol. 14 (Suppl.3): III63 (Abstr. 102).

Gorbunova V., Orel N., Besova N. Combined chemotherapy with docetaxel in extensive advanced gastric cancer (pilot study). 10th Internat. Congress Anti-Cancer Treatment.. Paris. — 2000. — P. 270.

Kim N.K., Park Y.S., Heo D.S. et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer // Cancer (Philad). 1993. — Vol. 71. P. 3813-3818.

Macdonald J.S., Schein P.S., Woolley P.V., et al. 5-fluorouracil, mitomycin-C, and Adriamycin (FAM): a new combination chemotherapy program for advanced gastric carcinoma // Ann Intern Med. 1980. — Vol. 93. — P. 533-536.

Murad A.M., Santiago F.F., Petroianu A. et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer // Cancer (Philad) 1993. - Vol. 72. — P. 37-41.

Pyrhonen S., Kuitunen T., Nyandoto P. et al. Randomised comparison between chemotherapy plus best supportive care with supportive care alone in patient with non-resectable gastric cancer // Br J Cancer 1995. — Vol. 71. — P. 587-591.

Scheithauer W., Kornek G., Hejna M. et al. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial // Ann Hematol. — 1994. — Vol. 73. — A. 181.

Wagner A.D., Groth W., Haerting J. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data // J Clin Oncol 2006. — Vol. 24. — P. 2903-09.

Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15: 261-267.

Wils J., Klein D.J., Wagener T.H. et al. Sequential high dose methotrexate and 5-fluorouracil combined with doxorubicin—a step ahead in the treatment of advanced gastric cancer: a trial of the EORTC Gastrointestinal Tract Cooperative Group // J Clin Oncol. — 1991. — Vol. 9. — P. 827-831.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...